The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That’s a hefty trade of 3.885m
Thanks for sharing @itsyou. It's kind of refreshing to see that NhS service providers CCL are adopting the Early CDT lung and praising its ease of use, accuracy and efficiency (process and cost).
This is great, especially because Early CDT lung has not yet really come out of its shell.
That's seems like a fair assessment @Flova28. I wonder whether the news about ONC looking into acquisition in that last RNS is actually the cause for the dip. Typically it is the acquiring company that then pays a premium and thus incurs higher debt obligations. The target company to be acquired would usually see a temporary boost. Now all in all it would form part of an exciting growth journey and set the stage for the new phase of growth.
Let's hope that in case an acquisition of a target company is in play we only see temporary dips.
Who knows, perhaps it is priced in and we see the shares spike....at the end of the day acquisitions increase market cap, value and can accelerate growth.
Very keen to learn more about what is on the cards.
A bit of news here
CCL now offers EarlyCDT Lung test - identifying lung cancer risk earlier
Company news, Oncology
4 August 2022
Cambridge Clinical Laboratories is now running the Oncimmune EarlyCDT Lung test in its Cambridge laboratory. The EarlyCDT Lung test is a simple finger prick blood test which results can indicate whether an individual has an increased risk of lung cancer.
A useful test for those worried about lung cancer, those whose family members have had it and those who have been exposed to environmental factors that may increase risk, such as smoking. EarlyCDT Lung can detect lung cancer on average four years before standard care and has shown, in a large NHS trial, that it can reduce late stage lung cancer presentation by 36%.*
The impact of Covid-19 isn’t isolated to just those getting the virus. The NHS is struggling, with waiting times for cancer referral and treatment at record high. With 80% of lung cancer cases diagnosed in the later stages of the disease this new availability of the EarlyCDT Lung test could make a huge difference.
CCL, based in Milton Cambridge, is a leading lab with an objective to bring new technologies for diagnostics to the UK.
CCL CEO Dr Anthony Cooke says: “2020 threw a huge curveball for the world in the form of the Covid-19 pandemic, as a result Cancer healthcare has been hugely impacted. The new tests we are launching will help to ease the pressure of the NHS and support patients to take more of a lead with their healthcare. CCL wants to help; we know our tests will improve the lives of many.”
https://www.camclinlabs.co.uk/news/earlycdt
With Alistair just on board and discussions about acquiring in the RNS we can assume we will acquire rather than be acquired Trek?
To make the statement they are looking at options would seem to indicate that companies have been identified, maybe some news in the near future?
This company has so much potential, just extremely frustrating with the wait..
Not sure when AR is but results end of month.
Likewise very frustrated here at lack of news.
Either acquiring or being acquired?
USB up to tricks again!
Who knows.
Usual caveats
Trek
Am not sure truth be told.
Very quiet times though, nothing to report on, minimal trades. Assume the team with Alistair now involved are pushing ahead. Would be great to see some momentum post Summer!
Still here and holding (avg about 1.30), annoying but not concerned.
ATB
And quiet it remained.....
Hey people! I know that ONC had completed their FY22 on May 30th. Annual report was due to be reported In September.
Does anyone know whether we will actually see the annual report in September or in January? They mentioned in their most recent RNS, that they are aligning the financial year to the wider market. Audited figures shall be reported at the start of 2023.
A bit of clarity would be nice if anyone knows
Thanks. Curiosity satisfied.
Ther are either divi shares reinvested and we don’t pay a divi so they are likely MM liquidity shares. MM’s often put through small trades to generate liquidity by moving the price on illiquid stocks. They can register a liquidity scheme under MiFID. Without the MM intervening stocks could become zero or infinite…
“Definition: market making incentive schemes that the Exchange is mandated to offer under Article 48(2)(b) of MiFID and Article 1 of Commission Delegated Regulation (EU) 2017/578
Page 58 covers it and also ALGO trades.
https://docs.londonstockexchange.com/sites/default/files/documents/rules-lse.pdf
MiFID2 MM agmt tab...
https://docs.londonstockexchange.com/sites/default/files/documents/20200401%20MIT%20&%20TE%20Parameters%20version%207.2.xls”
That’s sort of the gist why so many small numbers of trades.
Usual caveats
Trek
Just curious. If you bought the single share at 16.29 hrs today, why? Genuine curiosity!
Folks, I wouldn't get too excited here. Whilst you both might be right with run up to financials or acquisition I think the 10% bump is just market movements. The federal reserve is not indicating a 100bps rate hike but instead most likely 75bps. That incombination with decent results from some of the NA investment banks is softening recession fears to some degree.
I cannot tie this minor bump to anything ONC specific as of yet. Prove me wrong
Definitely oversold
Did cross my mind that, acquisition, but I think this little run could be due to AM buying.
I posted before that the finances must be sound to even contemplate an acquisition. I thought then we would move back to 100p at least but it went below 80. The problem is the market here is so thin and as you can see from today just a few trades can send us disproportionately up or down.
I have taken the opportunity to improve my average. There is plenty of headroom for the SP to respond to good news. Macro aside, up seems more likely than down as the options gate is still 200p, results end of August which should be v good. Chance of acquisition and expecting great things from AM!
Usual caveats
Trek
Maybe it's an acquisition of a smaller company coming through sooner rather than later? The run ahead of results I agree would be too early. Here's hoping for a nice RNS this week on something.
Usually worth following the money if there is a bounce like this. I grabbed 5k shares, 6k was NT, now only 900 shares left at 88p unless a sell comes in.
I have been expecting a run ahead of results. Didn’t think it would be this early so may just be a little recovery from oversold.
UBS London Branch should be buying again as well!
Anyways no idea but eyes and ears to the ground!
Usual caveats
Trek
I’m thinking there must be something good happening!?!
I suppose there is your rough timeline. 2 GBP in 12 months and 3.5GBP in 48 months time. I like the share price oriented vesting schedule. Let us now wait some more.
Good to see £2 still the gate.
AM must be confident to sign up!
Also others lapsed.
Quite refreshing really and SP related which is completely aligned with shareholders
Usual caveats
Trek
The SP drop is painful, surprised that the news last week didn't push it up but the market is what it is.
AM looks to be a great appointment - why would a CEO who was on $8m plus at Syneos join Onc if he didn't think there was potential. It's not like he needs the money and I assume his salary here (albeit with stock options?) is a fraction of what he got previously.
Definitely a LT hold due to the drop, I do wonder who we will potentially target acquisition wise.
As for the funding, it's a good q from Trek. We had that raise at a premium last year, maybe via family office?
Here's hoping for a good set of numbers hopefully soon!
Looks like the end of the bargains. Wonder if that large buy is AM. Perhaps tried to get 100k but stock not available.
Be nice to get a TR1 other than UBS!
Usual caveats
Trek
Maybe i got in too early.i understand the frustration you long term holders are feeling.
The new appointment is good for the company.
Maybe Patience is needed.
We are in the same boat. i am in on ONC for 4 years now. And we are below my original investment. I cannot solely blame ONC though because virtually any market or stock I put money in has tanked this year. In some sectors quite majorly. I am biting on the mouth piece a d trying to get through this collateral damage in one piece. I am ok now with not being able to afford a house because all my stocks are in the ****.....but at least the housing market is at a critical point to so not sure if its a good thing I need to wait 1 year or so to see stocks improve. My hands are tied with ONC. I really hope it goes up.
The fact that there is going to be a delayed earnings and only report on 'audited' numbers in Jan 2023 is also not ideal. But this is all part of the change process. Like Phoenix from the ashes Phoenix (onc) was never dead....it was just burried in a pile of dirt.
I completely agree with you but at the end of the day the SP is the main thing for us. I mean I hope things will turn but I can’t see it for a few years tbh. Alister does have a great track record so the business can only get better and further with a guy like this. It’s just the worry when the price goes down constantly on all your stocks.